Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marinos Dalakas MD, FAAN

Marinos C. Dalakas MD, FAAN

Professor of Neurology and Chief, Neuromuscular Division, Thomas Jefferson University, Philadelphia, Pennsylvania; Chief, Neuroimmunology Unit, National and Kapodistrian University of Athens, Athens, Greece

Dr. Marinos Dalakas is Professor of Neurology and Director of the Neuromuscular Division at Thomas Jefferson University School of Medicine in Philadelphia. He is Professor of Neurology and Chief of the Neuroimmunology Laboratory in the Department of Pathophysiology at the University of Athens Medical School in Athens, where he has been Emeritus Professor since 2016. Dr. Dalakas is a member of the American Neurological Association, the American Academy of Neurology, the European Neurological Society, and the International Society of Greek Neuroscientists, among other professional organizations.

He has published widely. His areas of research are broad and include neuroimmunology, neurovirology, immunogenetics, and immunotherapies in neurologic diseases. He has focused on immunopathogenesis of autoimmune neuropathies and myopathies, stiff-person syndrome and autoimmune hyper-excitability CNS disorders, and other autoimmune neurological disorders including multiple sclerosis, myelitis and amyloidosis. He has conducted several controlled clinical trials, including the first with intravenous immunoglobulin (IVIg) in autoimmune neurology.

He completed a 3-year fellowship training in neuromuscular diseases at the Medical Neurology Branch of the NINDS in Bethesda, Maryland, and an additional 5-year training in neuroimmunology/neurovirology at NINDS. He subsequently served as Chief of the Neuromuscular Diseases Section of the NINDS, NIH, a position he held for 20 years before joining Thomas Jefferson University.

Disclosures

  • Advisory board/honoraria: Sanofi; Octapharma; Grifols; Argenx; DDF (Drug Delivery & Formulation); Alexion; UCB
  • Honoraria: TAND (Therapeutic Advances in Neurological Disorders), N2 (Neurology, Neuroimmunology, Neuroinflammation); Neurodiem (for serving as Associate Editor)
  • Institutional grant support: (to Thomas Jefferson University or the University of Athens Medical School): Dysimmune Diseases Foundation, Nufactor; InfuCare; Merck Serono; Novartis